RedHill Biopharma (RDHL) Total Liabilities (2011 - 2025)

RedHill Biopharma (RDHL) has reported Total Liabilities for 15 consecutive years, with $21.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Liabilities fell 7.26% year-over-year to $21.1 million in Q4 2025; TTM through Dec 2025 was $21.1 million, a 7.26% decrease from a year earlier, with the FY2025 full-year figure at $21.1 million, down 7.26% from the prior year.
• Total Liabilities was $21.1 million for Q4 2025 at RedHill Biopharma, down from $22.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $207.3 million in Q4 2022 and troughed at $21.0 million in Q4 2023.
• A 5-year average of $109.9 million and a median of $167.1 million in 2021 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 67.36% in 2021 and plunged 89.88% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $172.3 million in 2021, then grew by 20.29% to $207.3 million in 2022, then sank by 89.88% to $21.0 million in 2023, then climbed by 8.33% to $22.7 million in 2024, then retreated by 7.26% to $21.1 million in 2025.
• The last three Total Liabilities figures came in at $21.1 million (Q4 2025), $22.8 million (Q2 2025), and $22.7 million (Q4 2024), per Business Quant data.